3-Methoxyeticyclidine (3-MeO-PCE), also referred to as methoxieticyclidine, is a dissociative anesthetic that shares qualitative similarities with PCE and PCP. It has gained prominence as a designer drug and has been made available through online channels.
On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom issued a report concerning methoxetamine. This report asserted that the potential harms associated with methoxetamine warranted its classification under Class B of the Misuse of Drugs Act (1971). Notably, this classification does not rely on the assessment of harm alone but encompasses various factors. The report also recommended that analogs of methoxetamine should be treated as Class B drugs and advocated for a comprehensive provision that includes both known and unexplored arylcyclohexamines, such as 3-MeO-PCE.
This report additionally detailed the receptor binding profiles of methoxetamine and three other dissociatives—3-MeO-PCP, 4-MeO-PCP, and 3-MeO-PCE. The research indicated a significant affinity for the PCP site of the NMDA receptor (NMDAR) and was subsequently elaborated upon in a more extensive publication.
Specifically, 3-MeO-PCE exhibits Ki values of 61 nM for the NMDAR, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor, and 525 nM for the σ2 receptor. These values provide insights into its pharmacological interactions and potential effects.

IUPAC name
CAS Number1364933-80-1 
PubChem CID57461569
Chemical and physical data
Molar mass233.355 g·mol−1

Legal status

3-MeO-PCE is prohibited in Sweden and Switzerland.
In accordance with Chile’s Ley de drogas, also known as Ley 20000[10], all esters and ethers of PCE are deemed illegal. Given that 3-MeO-PCE falls into the category of PCE ethers, it is consequently considered illegal under this legislation.


1. What is 3-MeO-PCE?

  • 3-MeO-PCE, or 3-Methoxyeticyclidine, is a dissociative anesthetic known for its effects on perception, consciousness, and sensory experiences.

2. What are the effects of 3-MeO-PCE?

  • The effects of 3-MeO-PCE can include altered sensory perceptions, dissociation from one’s body, and changes in consciousness. Users may also experience feelings of euphoria or stimulation.

3. Is 3-MeO-PCE legal?

  • The legal status of 3-MeO-PCE varies by country and jurisdiction. It’s essential to be aware of the specific laws in your region regarding the possession and use of this substance.

4. What are the potential risks associated with 3-MeO-PCE use?

  • Like many designer drugs, 3-MeO-PCE carries potential health risks and adverse effects. These may include unpredictable reactions, overdose, and long-term consequences. It can also be habit-forming if used regularly.

5. Is 3-MeO-PCE addictive?

  • While there may be a potential for psychological dependence with repeated use, it is not considered to be highly physically addictive like some other substances.

6. How can I reduce the risks associated with 3-MeO-PCE use?

  • If you choose to use 3-MeO-PCE, it is advisable to start with a low dose, be in a safe environment, and have someone you trust present. Avoid combining it with other substances, and be aware of its potential side effects.

7. What is the legal status of 3-MeO-PCE in my country?

  • The legal status of 3-MeO-PCE varies by country and region. To know the specific legal status in your area, consult local drug control and law enforcement agencies.

8. Where can I find help or support for 3-MeO-PCE-related issues?

  • If you or someone you know is facing challenges related to 3-MeO-PCE use or addiction, it’s essential to seek professional help. Reach out to addiction treatment centers, healthcare providers, or support groups for guidance and assistance.

9. What’s the best way to use 3-MeO-PCE safely?

  • It’s strongly recommended not to use 3-MeO-PCE. Engaging in any use of psychoactive substances, especially designer drugs, can be risky and should be avoided.

Please remember that this information is provided for educational purposes only. The use of designer drugs like 3-MeO-PCE can carry significant risks and legal implications. Always prioritize your health and safety and be aware of the laws in your area.


  1. Morris H, Wallach J (July–August 2014). “From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs”This comprehensive review explores the non-medical use of dissociative drugs, providing valuable insights into the history and prevalence of substances like methoxetamine (MXE).
  2. De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (June 2013). “From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine, and 3-methoxyphencyclidine and their determination in three biological matrices”This study offers analytical profiles of various dissociative drugs, including methoxetamine, shedding light on their presence in biological samples.
  3. Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, et al. (August 2016). “Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines”Delving into the synthesis and analytical characterizations of N-alkyl-arylcyclohexylamines, this research contributes to a deeper understanding of these substances.
  4. “3-MeO-PCE”. New Synthetic Drugs DatabaseThis database entry provides information on 3-MeO-PCE, a dissociative drug, and its properties.
  5. “Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012″This report from the UK Home Office presents findings and recommendations regarding the classification and regulation of methoxetamine.
  6. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (March 2013). “The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor”Exploring the pharmacological properties of ketamine analogs, including methoxetamine, this study investigates their affinity for glutamate NMDA receptors.
  7. “Elva nya ämnen klassas som narkotika eller hälsofarlig vara” (in Swedish). FolkhälsomyndighetenThis Swedish source discusses the classification of new substances as narcotics or potentially harmful substances, providing insights into regulatory changes.
  8. Riksdagsförvaltningen. “Förordning (1992:1554) om kontroll av narkotika” (in Swedish)This regulation outlines control measures related to narcotics in Sweden, including substances like methoxetamine.
  9. “Verordnung des EDI vom 30. Mai 2011 über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI)” (in German). Der BundesratThis German regulation provides details about the classification of controlled substances, including psychotropic compounds, within Germany.
  10. “SUSTITUYE LA LEY Nº 19.366, QUE SANCIONA EL TRAFICO ILICITO DE ESTUPEFACIENTES Y SUSTANCIAS SICOTROPICAS” (in Spanish). Biblioteca Del Congreso NacionalThis Spanish document discusses the amendment of a law related to the illicit trafficking of narcotics and psychotropic substances, providing insights into legal changes.

Leave a Comment

Your email address will not be published. Required fields are marked *